Protease Inhibitors: all 1,856 studies that test it

Page 6 of 19. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.

• Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)CompletedNCT01390428Phase 1Results posted
• BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis CCompletedNCT01389323Phase 3Results posted
• Genetics and HIV-1 Protease InhibitorsCompletedNCT01388543Phase 4Results posted
• Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01383928Phase 1/2Results posted
• Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersCompletedNCT01374802Phase 1Results posted
• Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)CompletedNCT01370642Phase 3Results posted
• Therapy to Elevate CD4 Counts in HIV-1 DiseaseCompletedNCT01370018Phase 2/3Results posted
• A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01366638Phase 3Results posted
• Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentCompletedNCT01363011Phase 3Results posted
• Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedNCT01359969Phase 2Results posted
• Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of CareCompletedNCT01359644Phase 2Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)CompletedNCT01358864Phase 3Results posted
• Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)CompletedNCT01353911Phase 2Results posted
• Switch to Unboosted Atazanavir With Tenofovir StudyCompletedNCT01351740Phase 4Results posted
• The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic StudyCompletedNCT01348763Phase 1Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)CompletedNCT01343888Phase 3Results posted
• Drug Drug Interaction of BI 201335 and TenofovirCompletedNCT01340196Phase 1Results posted
• Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric PatientsCompletedNCT01335698Phase 3Results posted
• Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01335685Phase 1/2Results posted
• A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedNCT01330316Phase 3Results posted
• Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain AmyloidosisCompletedNCT01318902Phase 1Results posted
• Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected SubjectsCompletedNCT01314261Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT01306617Phase 2Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedNCT01297270Phase 3Results posted
• A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected PatientsCompletedNCT01292239Phase 3Results posted
• A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based TherapyCompletedNCT01290731Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected ParticipantsCompletedNCT01290679Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected PatientsCompletedNCT01289782Phase 3Results posted
• A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based TherapyCompletedNCT01288209Phase 3Results posted
• An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous TherapyCompletedNCT01281839Phase 3Results posted
• TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRVCompletedNCT01281813Phase 3Results posted
• Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus InfectionCompletedNCT01257204Phase 2Results posted
• A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)TerminatedNCT01243762Phase 1Results posted
• VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT01241760Phase 3Results posted
• Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas CancerCompletedNCT01232829Phase 2Results posted
• Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV InfectionCompletedNCT01232127Phase 4Results posted
• A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)CompletedNCT01221298Phase 2Results posted
• A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01217957Phase 1/2Results posted
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerTerminatedNCT01217411Phase 1/2Results posted
• Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin DeficiencyCompletedNCT01213043Phase 2Results posted
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate CancerTerminatedNCT01200810Phase 2Results posted
• A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced PatientsCompletedNCT01199939Phase 2Results posted
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic MelanomaCompletedNCT01196416Phase 1/2Results posted
• Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic SuppressionTerminatedNCT01194856Phase 4Results posted
• RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line ChemotherapyTerminatedNCT01193868Phase 2Results posted
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant GliomaTerminatedNCT01189240Phase 1/2Results posted
• A Research Trial of Aralast in New Onset Diabetes (RETAIN)TerminatedNCT01183468Phase 1Results posted
• RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01175343Phase 2Results posted
• A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing GuidelinesCompletedNCT01172535Phase 2/3Results posted
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior TreatmentCompletedNCT01170962Phase 2Results posted
• Pyronaridine Artesunate-Ritonavir Drug-drug Interaction StudyCompletedNCT01156389Phase 1Results posted
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1/2Results posted
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerTerminatedNCT01151449Phase 2Results posted
• A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) TherapyCompletedNCT01141569Phase 2Results posted
• Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCompletedNCT01132313Phase 2Results posted
• Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve PatientsCompletedNCT01125189Phase 2Results posted
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedNCT01122901Phase 2Results posted
• A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)CompletedNCT01120600Phase 3Results posted
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaTerminatedNCT01120275Phase 2Results posted
• RO4929097 in Treating Patients With Metastatic Colorectal CancerCompletedNCT01116687Phase 2Results posted
• Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)TerminatedNCT01108666Phase 2Results posted
• A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)CompletedNCT01102972Phase 4Results posted
• PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)CompletedNCT01099579Phase 3Results posted
• Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade GliomaTerminatedNCT01095094Phase 2Results posted
• A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072CompletedNCT01074008Phase 2Results posted
• Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)TerminatedNCT01068873Phase 4Results posted
• Safety and Tolerability of Odanacatib (0822-059)CompletedNCT01068262Phase 1Results posted
• Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and NeckCompletedNCT01065844Phase 2Results posted
• Drug-Drug Interaction of Lopinavir/Ritonavir on PitavastatinCompletedNCT01057433Phase 4Results posted
• VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir PlaceboCompletedNCT01054573Phase 3Results posted
• Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01054170Phase 2Results posted
• A Study of Semagacestat for Alzheimer's PatientsCompletedNCT01035138Phase 3Results posted
• Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/FormoterolCompletedNCT01023516Phase 2Results posted
• Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)CompletedNCT01017575Phase 2Results posted
• Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese PatientsCompletedNCT01016912Phase 2Results posted
• A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)CompletedNCT01010906Phase 1Results posted
• Roll-Over Protocol To Provide Atv And/Or Truvada For Extended AccessCompletedNCT01003990Phase 3Results posted
• A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)CompletedNCT00998985Phase 1Results posted
• A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected PatientsCompletedNCT00996476Phase 2Results posted
• Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin AloneCompletedNCT00995345Phase 2Results posted
• Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1CompletedNCT00993148Phase 2Results posted
• Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant WomenCompletedNCT00993031Phase 3Results posted
• Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.CompletedNCT00985543Phase 1Results posted
• Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)CompletedNCT00984620Phase 2Results posted
• Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female SubjectsCompletedNCT00983957Phase 1Results posted
• Drug-Drug Interaction Between Colchicine and RitonavirCompletedNCT00983515Phase 1Results posted
• A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard TreatmentCompletedNCT00980330Phase 2Results posted
• HIV Protease Inhibitors for the Prevention of Malaria in Ugandan ChildrenCompletedNCT00978068Phase 3Results posted
• Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT00963820Phase 1Results posted
• Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)TerminatedNCT00954993Phase 1Results posted
• A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With TiotropiumCompletedNCT00949975Phase 2Results posted
• Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIVCompletedNCT00949234Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) PatientsCompletedNCT00947349Phase 2Results posted
• A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)CompletedNCT00943761Phase 2Results posted
• Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART RegimensCompletedNCT00940771Phase 4Results posted
• Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple MyelomaCompletedNCT00932698Phase 1Results posted
• BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.CompletedNCT00931801Phase 4Results posted
• Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)CompletedNCT00928187Phase 3Results posted
• A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected ChildrenCompletedNCT00919854Phase 2Results posted
• A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected AdolescentsCompletedNCT00915655Phase 2Results posted

← Protease Inhibitors overview